Abstract 18P
Background
Immunotherapy (IO) has become an important component of systemic treatment in early-stage triple-negative breast cancer (eTNBC). Considering toxicity and financial burden, identifying reliable biomarkers of response is urgently warranted. Therefore, we investigated blood cell DNA methylation profiles as biomarker for achieving a pathologic complete response (pCR) at surgery after neoadjuvant chemoimmunotherapy.
Methods
eTNBC patients receiving systemic chemoimmunotherapy before surgery at the Medical University of Vienna were included in this analysis. DNA from peripheral blood mononuclear cells (PBMCs) was isolated from whole blood samples collected at start of neoadjuvant therapy and methylation profiling was performed with Infinium Methylation EPIC microarrays. Routine histologic work-up from surgery determined a pCR or non-pCR according to pathologic standard procedures.
Results
Seven eTNBC patients (all women), median age of 63 years (range 40-83 years), were available for this analysis. All patients received neoadjuvant chemoimmunotherapy with pembrolizumab plus weekly paclitaxel/carboplatin followed by pembrolizumab plus epirubicin/cyclophosphamide. Three out of 7 (42.9%) patients achieved a pCR, while 4/7 (57.1%) had residual disease at surgery. Notably, when focusing on their methylation patterns, patients with pCR and non-pCR could be clearly segregated into two distinct groups. This distinction was based on the methylation profiles of the top 500 differentially methylated CpG sites.
Conclusions
Our results revealed differentially methylated genes between patients w/o pCR that might play a role in response to chemoimmunotherapy. Blood cell methylation profiles might serve as predictive biomarker for pCR in eTNBC and larger patient cohorts are needed to validate our findings.
Legal entity responsible for the study
The authors.
Funding
Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna.
Disclosure
A.M. Starzer: Financial Interests, Personal, Invited Speaker, Lecture honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant, Industry partner of institutional Christian Doppler Laboratory: Roche; Non-Financial Interests, Personal, Member, National Oncology Society: OeGHO; Non-Financial Interests, Personal, Member, Oncology society of USA: ASCO; Other, Personal, Other, Travel support for conference participation: MSD, Lilly. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer Ingelheim, Bristol Meyers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Personal, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Personal, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Personal, Other, Member Multi-Site Guideline Advisory Group: ASCO. R. Bartsch: Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen, Roche, Novartis, Eli-Lilly, Pierre Fabre, Daiichi, Gilead, MSD, Pfizer, Eisai, Gruenenthal; Financial Interests, Personal, Advisory Board: Daiichi, AstraZeneca, Roche, Novartis, Eli Lilly, Pierre Fabre, MSD, Gilead, Seagen, Eisai, Gruenenthal; Financial Interests, Institutional, Funding, Investigator Initiated Trial: Daiichi; Financial Interests, Institutional, Coordinating PI, Drug support for investigator initiated trial: MSD. A.S. Berghoff: Financial Interests, Personal, Research Funding: Daiichi Sankyo, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, Bristol Meyers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa; Financial Interests, Personal, Other, travel support: Roche; Financial Interests, Personal, Other, Travel support: Amgen, AbbVie. All other authors have declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display